

LumaCare

Press Release

28 February 2006

For Immediate Release

LumaCare® Appoints

**Lynton Lasers Ltd., as the official Master Distributor for
European Union**

NEWPORT BEACH, CALIFORNIA – LumaCare® the leading supplier of non Coherent Light Sources for Photodynamic Therapies (PDT) and Dermatological conditions, today announces the appointment of Lynton Lasers Ltd. as the Master Distributor for the LumaCare LC-122M CE-MDD medically certified light sources within the entire European Community.



Lynton Lasers currently distributes medical lasers and IPL light sources into the cosmetic, medical and aesthetic market. Dr Andrew Charlton Managing Director stated “the addition of LumaCare® products into our channel provides Lynton with a complete one stop source for any practitioner or Medical Clinic seeking the latest in light based therapeutic devices. Furthermore, PDT is one of the most exciting fields in medicine and Lynton is well position to meet this emerging market. The LC-122M is safe, affordable, flexible, and is now proven an effective solution for Protocols utilizing PDT Drugs such as: ALA, 5-ALA, Foscan®, Levulan®, Metex®, Photofrin®, and others”.

- more - -

The LumaCare LC-122M is suitable for all medical disciplines including Veterinary, Dermatology, Oncology, Ophthalmology, and Dental. It is an affordable solution, for pharmaceutical partners to bundle the LC-122M with new PDT protocol introductions. For physicians and patients, it is a safe and effective PDT drug activation system. This simple and cost-effective approach will appeal to medical insurers and facilitate medical reimbursement.

PDT is one of the most exciting emerging fields of medicine, the non-invasive treatment of tissue diseases and disorders. Photosensitive drugs are applied on the skin and penetrate through to the diseased tissue, or they are injected into the blood stream from which the affected area absorbs the drug. Once the drugs are in place, they may be selectively activated via specific light frequencies. The LumaCare lamp activates the drugs by irradiating the tissues with a fixed frequency light source unique to each drug and disease. The drugs absorb the targeted light, which then stimulate them to destroy only the diseased tissues that have absorbed the drugs.

Lynton Lasers Ltd is globally acknowledged as a leading British company specializing in the design, development and manufacture of laser and light systems for niche applications. Lynton Lasers Ltd., is a privately held firm located in Holmes Chapel UK with over ten years experience in light based technologies for a wide range of cosmetic and medical applications.

LumaCare® is an operating unit of MBG Technologies. LumaCare's charter is to design and market simple, safe, reliable, and low cost Light Sources into the Medical market as a viable alternative to complex and capital intensive laser and LED based systems. LumaCare was founded over 10 years ago and the parent company MBG Technologies was founded in 1990.

For additional information or to place an order, please visit our web site at www.LumaCare.com, or e-mail: info@LumaCare.com.

In European Community, contact our Distributor, Lynton Lasers, at Phone: +44 (1477) 5369777.

In the USA, please call the Newport Beach, CA office at 1-949-422-1963.

end

All registered trademarks (®) are property of their respective companies/owners.